Colin Hill
Board Member
Fulcrum Therapeutics, Inc. (FULC)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Colin Hill
Colin Hill is recorded as Board Member at Fulcrum Therapeutics, Inc. (FULC). Fulcrum Therapeutics, Inc. reported in an 8-K filed June 17, 2024 that Colin Hill was appointed Class I director, effective June 17, 2024.
“On June 17, 2024, the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, increased the size of the Board from eight to nine members, and upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Colin Hill as a member of the Board, effective June 17, 2024, to serve as a Class I director with a term expiring at Fulcrum's 2026 annual meeting of stockholders and thereafter until his successor has been duly elected and qualified or until his earlier death, resignation or removal.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-06-17–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Fulcrum Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Alex C. Sapir CEO, Board Member
- Bryan Stuart CEO, COO, Board Member
- Robert J. Gould CEO
- Kate Haviland Chairman
- Mark Levin Chairman
- Alan A. Musso CFO
- Peter Thomson CFO
- Robert E. Gould CFO
- Mel Hayes COO
- Alan Musso Chief Accounting Officer
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.